As More Products Get Priority Review, User Fee Cost Gap From Standard Review Is Narrowing

US FDA’s priority review voucher fee will decrease again in FY 2022 as the cost of a priority assessment continues to trend closer to the cost of a standard assessment.

Priority seats
The FDA has been conducting an increasing number of priority assessments of NME NDAs and BLAs in recent years. • Source: Alamy

The difference between the cost of standard and priority assessments continues to narrow, a signal not only of the growing popularity of expedited pathways, but also that the US Food and Drug Administration eventually may not need a full 12 months to determine the fate of an application.

Embedded in the calculations for the FY 2022 material threat medical countermeasure, rare pediatric disease, and tropical disease priority review voucher redemption fees, published 30 September in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from User Fees

More from Pathways & Standards